SPbNIIVS will receive 500 million rubles to pay off accounts payable

The government does not name the total amount of debt. The funds will be allocated by FMBA in 2025. The financial recovery program of SPbNIIVS is planned for the period from 2024 to 2030. The institute received a similar subsidy in the amount of 500 million rubles in November 2024.

FMBA must monitor the targeted and effective use of budgetary allocations and submit a report to the government by February 1, 2026.

According to SPARK-Interfax, FSUE SPbNIIVS FMBA of Russia was registered in St. Petersburg in 1994. Since November 2024, 100% of the institute's shares have been owned by the state. Since December 2023, the acting director of the research institute is Konstantin Pokachalov.

According to Rusprofile, the institute last disclosed revenue data in 2021. At that time, it was 2.9 billion rubles (a 37% drop compared to the previous year), and the loss was at the level of 472 million rubles (a 168% drop). At that time, the organization had already identified risks of losing financial stability due to the fact that the institute had a high share of borrowed funds, and the debt-to-equity ratio was 2.17. In 2021, the organization showed a tendency to lose solvency.

SPbNIIVS is a full-cycle developer and manufacturer of a number of medicinal, prophylactic and diagnostic drugs. The research institute includes two research and development centers - in St. Petersburg and Nicaragua. The main areas of work of the institute are the creation of new high-tech drugs based on recombinant technologies based on E. coli, the development of recombinant drugs de novo on various platforms and a number of other studies.

At the end of October 2024, the research institute posted a tender to find a contractor to conduct phase III clinical trials (CT) of the 16-valent pneumococcal vaccine (PCV-16). The initial maximum contract price is 279.8 million rubles. The contractor must evaluate the immunogenicity, safety and tolerability of the vaccine developed by the FMBA institute in comparison with Prevenar-13, a pneumococcal vaccine from the American Pfizer. The contract was signed in early December of the same year with St. Petersburg-based EXELLENA LLC for 245 million rubles.

A month later, SPbNIIVS announced another tender for conducting a clinical trial of the MCV-5 vaccine for the prevention of meningococcal infections. The cost of the purchased work was then estimated at 430 million rubles. During the clinical trial, the contractor must study the effectiveness and safety of the drug from the FMBA institute in comparison with the Menactra vaccine from the French pharmaceutical company Sanofi. A contract for 414.769 million rubles was also concluded with the company "EKSELLENA".